Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2017 08:30 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma and Mayoly Spindler Announce MS1819-SD Investigational Medicinal Product Dossier (IMPD) Submission

BROOKLYN, N.Y., Oct. 20, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), announced the submission of an Investigational Medicinal Product Dossier (IMPD) for...
October 16, 2017 08:30 ET | Source: AzurRx BioPharma, Inc.

AzurRx Announces Addition of Dr. Vern Lee Schramm to the Board of Directors

NEW YORK, Oct. 16, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”) a company specializing in the development of non-systemic, recombinant therapies for ...
September 27, 2017 08:30 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma and Mayoly-Spindler Announce Positive MS1819-SD Phase II Data in Exocrine Pancreatic Insufficiency (EPI)

BROOKLYN, N.Y., Sept. 27, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma Inc.(NASDAQ:AZRX) (“AzurRx” or the “Company”), today provided an update on the first six treated patients in its ongoing Phase IIa...
September 25, 2017 08:30 ET | Source: AzurRx BioPharma, Inc.

AzurRx Announces Appointment of Maged Shenouda as Chief Financial Officer

NEW YORK, Sept. 25, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”) a company specializing in the development of non-systemic, recombinant therapies for ...
August 24, 2017 08:00 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference on September 12

BROOKLYN, N.Y., Aug. 24, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...
August 23, 2017 08:00 ET | Source: AzurRx BioPharma, Inc.

AzurRx Reaches 6th Patient Enrollment of Phase IIa Trial of MS1819 for Treatment of Exocrine Pancreatic Insufficiency Associated with Chronic Pancreatitis

Results on First Six Patients Expected in September Company Adds Additional Clinical Trial Site to Further Support Enrollment in this Study and Other Planned Future Studies BROOKLYN, N.Y., Aug. 23,...
June 08, 2017 08:00 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Announces Closing of $5.0 Million Private Financing

BROOKLYN, N.Y.,, June 08, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc.(NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...
June 05, 2017 16:30 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma to Present at the 2017 LD Micro Invitational Conference (June 6) and the 2017 Marcum MicroCap Conference (June 15)

BROOKLYN, N.Y., June 05, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc.(NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...
April 11, 2017 08:00 ET | Source: AzurRx BioPharma, Inc.

AzurRx Provides Update on MS1819 Phase II Trial

Initial patient experience shows no safety issues MS1819 appears active, as demonstrated by CFA increases >20% at various dosing levels BROOKLYN, N.Y., April 11, 2017 (GLOBE NEWSWIRE) -- AzurRx...
March 08, 2017 09:32 ET | Source: AzurRx BioPharma, Inc.

AzurRx Announces Addition of Charles J Casamento to the Board of Directors

NEW YORK, March 08, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”) a company specializing in the development of non-systemic, recombinant therapies...